Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results



    TORONTO, May 13 /CNW/ - Transition Therapeutics Inc. ("Transition" or the
"Company") (TSX: TTH; NASDAQ:   TTHI), a product-focused biopharmaceutical
company developing therapeutics for disease indications with large markets,
today announced its financial results for the quarter ended March 31, 2009.

    
    Selected Highlights
    -------------------
    During the third quarter of fiscal 2009 and up to the date of this press
release, the Company achieved the following significant milestones:

    ELND005 (AZD-103) - Alzheimer's Disease:

    -   On April 23, 2009, Elan Pharma International Limited ("Elan") and
        Transition announced the receipt of a key US patent for Alzheimer's
        Disease Treatment with ELND005 (AZD-103);

    TT-223 - Diabetes:

    -   On March 23, 2009, Transition announced the Initiation of a Phase Ib
        clinical study of TT-223 in combination with a GLP-1 analogue in
        patients with type 2 diabetes;

    -   On February 5, 2009, Transition announced the completion of patient
        enrolment for a Phase II clinical study of gastrin analogue, TT-223,
        in patients with type 2 diabetes;

    Corporate Developments:

    -   In January 2009, the Company disposed of 23,272,633 shares of Stem
        Cell Therapeutics Corp. ("Stem Cell") in open market transactions
        over the TSX Venture Exchange which resulted in net proceeds of
        approximately $1.4 million.

    Pipeline Review
    ---------------
    

    ELND005 (AZD-103) for Alzheimer's Disease

    Transition's lead Alzheimer's disease compound ELND005 (AZD-103) is a
disease modifying agent with the potential to both prevent and reduce disease
progression, and improve symptoms such as cognitive function.
    In September 2006, Transition announced a global collaboration with Elan
to develop and commercialize ELND005 (AZD-103). In April 2007, Transition
announced that the FDA granted Fast Track designation to the investigational
drug candidate ELND005 (AZD-103).
    On October 20, 2008, Elan and Transition announced the patient enrollment
target for its randomized, double-blind, placebo-controlled, dose-ranging,
safety and efficacy Phase 2 clinical study of ELND005 (AZD-103) in patients
with Alzheimer's disease was achieved. The study will evaluate both cognitive
and functional endpoints, and each patient's participation is planned to last
approximately 18 months.
    On April 23, 2009, Elan and Transition announced the receipt of a key
patent for Alzheimer's Disease Treatment with ELND005 (AZD-103). The United
States Patent and Trademark Office issued US patent number 7,521,481 on April
21, 2009. The patent is entitled "Methods of Preventing, Treating and
Diagnosing Disorders of Protein Aggregation," and generally claims methods for
treating Alzheimer's disease comprising administering scyllo-inositol ELND005
(AZD-103). The patent will expire in the year 2025 or later due to any patent
term extensions.

    TT-223 for Diabetes

    On March 13, 2008, Lilly and the Company entered into a licensing and
collaboration agreement granting Lilly exclusive worldwide rights to develop
and commercialize Transition's gastrin based therapies, including the lead
compound TT-223, which is currently in early Phase II testing. Under the terms
of the agreement, Transition has received a US$7 million upfront payment, and
may also receive up to US$130 million in potential development and sales
milestones, as well as royalties on sales of gastrin based therapies if any
product is successfully commercialized.
    Transition and Lilly are both funding the Phase II clinical trial with
lead compound TT-223 in type 2 diabetes. Upon completion of this trial, Lilly
will be responsible for further development activities and the
commercialization of all gastrin-based therapeutic products worldwide.
    In August 2008, Transition and its collaboration partner Lilly initiated
a Phase II trial evaluating TT-223 in type 2 diabetes patients receiving
metformin and/or thiazolidinediones (TZDs) which completed enrolling patients
in February 2009.
    On March 23, 2009, Transition announced the initiation of a Phase Ib
clinical study of TT-223 in combination with a GLP-1 analogue in patients with
type 2 diabetes. The study is a randomized, double-blind, placebo-controlled
study in approximately 140 patients to evaluate the safety, tolerability and
efficacy of daily TT-223 treatments in combination with weekly administrations
of GLP-1 analogue, for a combination treatment period of 4 weeks with a
5-month follow-up.

    Juvenile Diabetes Research Foundation ("JDRF")

    In September 2006, the Company entered into an agreement with the JDRF to
support the clinical development of TT-223 in combination with GLP1 analogues
for the treatment of type 1 diabetes over a two year period.
    The original objective of the JDRF funding was to support efforts towards
the development of an effective gastrin-based therapy for diabetes. The
research funding used to date has supported meaningful work that has advanced
the TT-223 combination therapies into position to begin clinical studies.
Lilly will be fully supporting this clinical development work not only through
financial resources, but through their expertise and specialized clinical
development groups. With this in mind, Transition and the JDRF agreed that it
would be reasonable for the JDRF to reassign financial resources earmarked for
development of gastrin-based therapies to another worthy research program.
    Accordingly, on April 3, 2009, the Company terminated the agreement with
the JDRF and paid $441,455 (US$350,000) which represents the total amounts
owing to the JDRF under the terms of the agreement. The Company has no further
obligations that survive termination of the agreement.

    
    Drug Discovery Group
    --------------------
    

    On March 31, 2009 the Company's Board of Directors approved the closure
of operations at the Transition Therapeutics (USA) Inc. facilities located in
the United States. The decision to close the subsidiary was part of a
reorganization of the Company's drug discovery group which resulted in the
relocation of certain activities to the Toronto based facility. The Company
continues to pursue a number of discovery programs to advance novel lead
molecules into pre-clinical development, including the compounds acquired from
Forbes Medi-Tech (Research) Inc.

    
    Financial Review
    ----------------

    Results of Operations
    

    For the three-month period ended March 31, 2009, the Company recorded a
net loss of $5,738,815 ($0.25 per common share) compared to a net loss of
$4,977,020 ($0.22 per common share) for the three-month period ended March 31,
2008.
    For the nine-month period ended March 31, 2009, the Company recorded a
net loss of $15,644,881 ($0.68 per common share) compared to a net loss of
$10,628,206 ($0.46 per common share) for the nine-month period ended March 31,
2008.
    The increase in net loss of $761,795 or 15% for the three-month period
ended March 31, 2009 is primarily due to a decrease in interest income, the
loss on the sale of the SCT shares, and increases in both research and
development and general and administrative expenses. The increase in net loss
was partially offset by an increase in foreign exchange gains resulting from
the Company's US dollar investments.
    The increase in net loss of $5,016,675 or 47% for the nine-month period
ended March 31, 2009 is primarily due to an increase in research and
development expenses relating to the ELND005 (AZD-103) program and increases
in general and administrative expenses. The increase in net loss is also
attributed to decreases in revenue, interest income and gain on note
receivable. The increase in net loss was partially offset by foreign exchange
gains resulting from the Company's US dollar investments.

    Research and Development

    Research and development expenses increased $112,370 from $3,780,429 for
the three-month period ended March 31, 2008 to $3,892,799 for the three-month
period ended March 31, 2009. For the nine-month period ended March 31, 2009,
research and development expenses increased $3,786,306 to $12,812,657 from
$9,026,351 for the same period in fiscal 2008. For the three and nine-month
periods ended March 31, 2009, these increases were primarily the result of
significant increases in clinical development costs due to the ongoing Phase
II ELND005 (AZD-103) trial, preclinical costs associated with advancing the
family of compounds acquired in the NeuroMedix transaction, and increased drug
development costs.
    During the three-month period ending March 31, 2009, the Company incurred
decreased direct clinical program expenses relating to the TT-223 program.
However, during the nine-month period ended March 31, 2009, these costs
increased significantly. In light of the reimbursement of costs from Lilly,
there was an overall decrease in the program costs for the three and
nine-month periods ended March 31, 2009.

    General and Administrative

    During the three-month period ended March 31, 2009, general and
administrative expenses increased $155,321 to $1,611,629 from $1,456,308 for
the same period in fiscal 2008. For the nine-month period ended March 31,
2009, general and administrative expenses increased $488,763 to $4,783,451
from $4,294,688 for the same nine-month period in fiscal 2008. The increases
in general and administrative expenses for the three and nine-month periods
ended March 31, 2009 are due to increased stock option expenses, salaries and
facility expenses. These increases have been partially offset by decreases in
insurance, professional and regulatory costs as the comparative periods
contained increased costs associated with the NASDAQ listing of August, 2007.

    Amortization

    Amortization for the three-month period ended March 31, 2009, decreased
$38,577 to $690,752 as compared to $729,329 for the three-month period ended
March 31, 2008. For the nine-month period ended March 31, 2009, amortization
increased $120,596 to $2,173,149 as compared to $2,052,553 for the same period
in fiscal 2008.
    The three-month period decrease in amortization expense is primarily due
to reduced amortization expense relating to the workforce acquired from
Protana due to second quarter workforce reductions. The reduction in
amortization expense was partially off-set by the amortization expense
resulting from the assets acquired from Forbes during the first quarter of
fiscal 2009. The nine-month period increase in amortization expense is due to
increased amortization expense relating to the workforce acquired from Protana
due to a workforce reduction, the full-quarter impact of amortizing the
additional consideration paid to acquire the ENI technology in December, 2007
and the amortization expense resulting from the assets acquired from Forbes.

    Interest Income, net

    Interest income for the three-month period ended March 31, 2009 was
$170,553 as compared to $638,959 for the same period in fiscal 2008, resulting
in a decrease of $468,406. For the nine-month period ended March 31, 2009,
interest income was $930,682 as compared to $1,927,990 for the same period in
fiscal 2008, resulting in a decrease of $997,308. The decreases in interest
income resulted from decreases in effective interest rates.

    
    About Transition
    ----------------
    

    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the
treatment of diabetes. Transition has an emerging pipeline of preclinical drug
candidates acquired externally or developed internally using its proprietary
drug discovery engine. Transition's shares are listed on the NASDAQ under the
symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit
www.transitiontherapeutics.com.

    
    Extracts of the Financial Statements to Follow:

    CONSOLIDATED BALANCE SHEETS
    (Unaudited)

                                                     March 31,       June 30,
                                                         2009           2008
    -------------------------------------------------------------------------
                                                            $              $
    ASSETS
    Current
    Cash and cash equivalents                      27,295,575     22,952,865
    Held-to-maturity investments                   24,819,789     40,710,765
    SCT receivable                                          -      1,650,000
    Due from Eli Lilly and Company                    720,246        472,220
    GST and other receivables                         303,835        278,784
    Investment tax credits receivable                 993,057        693,057
    Prepaid expenses and deposits                   1,424,254        974,426
    -------------------------------------------------------------------------
    Total current assets                           55,556,756     67,732,117
    Capital assets, net                               807,042        958,689
    Intangible assets                              25,163,700     26,185,155
    -------------------------------------------------------------------------
                                                   81,527,498     94,875,961
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' EQUITY
    Current
    Accounts payable and accrued liabilities        1,765,202      1,576,190
    Due to Elan Pharma International Limited        1,888,631      1,795,242
    -------------------------------------------------------------------------
    Total current liabilities                       3,653,833      3,371,432
    Deferred revenue                               27,736,750     27,736,750
    Leasehold inducement                               71,450         80,024
    -------------------------------------------------------------------------
    Total liabilities                              31,462,033     31,188,206
    -------------------------------------------------------------------------

    Research and development commitments
    Guarantees


    Shareholders' equity
    Common shares                                 160,471,098    160,262,540
    Contributed surplus                             4,552,692      4,492,251
    Stock options                                   4,847,327      3,093,735
    Deficit                                      (119,805,652)  (104,160,771)
    -------------------------------------------------------------------------
    Total shareholders' equity                     50,065,465     63,687,755
    -------------------------------------------------------------------------
                                                   81,527,498     94,875,961
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    CONSOLIDATED STATEMENTS OF LOSS
    (Unaudited)

                     Nine-month     Nine-month    Three-month    Three-month
                   period ended   period ended   period ended   period ended
                       March 31,      March 31,      March 31,      March 31,
                           2009           2008           2009           2008
                              $              $              $              $
    -------------------------------------------------------------------------
    REVENUES
    Licensing fees            -      1,596,722              -              -
    -------------------------------------------------------------------------
                              -      1,596,722              -              -
    EXPENSES
    Research and
     development     12,812,657      9,026,351      3,892,799      3,780,429
    General and
     administrative   4,783,451      4,294,688      1,611,629      1,456,308
    Amortization      2,173,149      2,052,553        690,752        729,329
    Foreign
     exchange gain   (3,469,281)      (570,674)      (551,105)      (350,087)
    Loss (gain) on
     disposal of
     capital assets       6,137              -         (4,157)             -
    -------------------------------------------------------------------------
                     16,306,113     14,802,918      5,639,918      5,615,979
    -------------------------------------------------------------------------
    Loss before
     the following: (16,306,113)   (13,206,196)    (5,639,918)    (5,615,979)
    Interest income     930,682      1,927,990        170,553        638,959
    Loss on
     available-for-sale
     investments       (269,450)             -       (269,450)             -
    Gain on note
     receivable               -        650,000              -              -
    -------------------------------------------------------------------------
    Net loss and
     comprehensive
     loss for the
     period         (15,644,881)   (10,628,206)    (5,738,815)    (4,977,020)
    -------------------------------------------------------------------------

    Basic and
     diluted net
     loss per
     common share         (0.68)         (0.46)         (0.25)         (0.22)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC, SEC or otherwise. Except for historical information, this press
release may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical trials. These
statements are based upon the current expectations and beliefs of Transition's
management and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include factors
beyond Transition's control and the risk factors and other cautionary
statements discussed in Transition's quarterly and annual filings with the
Canadian commissions.





For further information:

For further information: visit www.transitiontherapeutics.com, or
contact: Dr. Tony Cruz, Chief Executive Officer, Transition Therapeutics Inc.,
Phone: (416) 260-7770, x.223, tcruz@transitiontherapeutics.com; Elie Farah,
President & Chief Financial Officer, Transition Therapeutics Inc., Phone:
(416) 260-7770, x.203, efarah@transitiontherapeutics.com

Organization Profile

Transition Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890